520 related articles for article (PubMed ID: 31042083)
1. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis.
Barnes JW; Duncan D; Helton S; Hutcheson S; Kurundkar D; Logsdon NJ; Locy M; Garth J; Denson R; Farver C; Vo HT; King G; Kentrup D; Faul C; Kulkarni T; De Andrade JA; Yu Z; Matalon S; Thannickal VJ; Krick S
Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L141-L154. PubMed ID: 31042083
[TBL] [Abstract][Full Text] [Related]
2. Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis.
Huang Q; Chen Y; Shen S; Wang Y; Liu L; Wu S; Xu W; Zhao W; Lin M; Wu J
Aging (Albany NY); 2020 Apr; 12(7):5812-5831. PubMed ID: 32244228
[TBL] [Abstract][Full Text] [Related]
3. CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
Tsoyi K; Liang X; De Rossi G; Ryter SW; Xiong K; Chu SG; Liu X; Ith B; Celada LJ; Romero F; Robertson MJ; Esposito AJ; Poli S; El-Chemaly S; Perrella MA; Shi Y; Whiteford J; Rosas IO
Am J Respir Crit Care Med; 2021 Aug; 204(3):312-325. PubMed ID: 33784491
[No Abstract] [Full Text] [Related]
4. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.
Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD
J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF.
Ebener S; Barnowski S; Wotzkow C; Marti TM; Lopez-Rodriguez E; Crestani B; Blank F; Schmid RA; Geiser T; Funke M
Am J Physiol Lung Cell Mol Physiol; 2017 Jan; 312(1):L42-L55. PubMed ID: 27815256
[TBL] [Abstract][Full Text] [Related]
7. Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia.
Krick S; Baumlin N; Aller SP; Aguiar C; Grabner A; Sailland J; Mendes E; Schmid A; Qi L; David NV; Geraghty P; King G; Birket SE; Rowe SM; Faul C; Salathe M
Sci Rep; 2017 Oct; 7(1):14388. PubMed ID: 29085059
[TBL] [Abstract][Full Text] [Related]
8. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-18 promotes fibroblast senescence in pulmonary fibrosis through down-regulating Klotho expression.
Zhang LM; Zhang J; Zhang Y; Fei C; Wang L; Yi ZW; Zhang ZQ
Biomed Pharmacother; 2019 May; 113():108756. PubMed ID: 30870716
[TBL] [Abstract][Full Text] [Related]
10. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.
Oruqaj G; Karnati S; Vijayan V; Kotarkonda LK; Boateng E; Zhang W; Ruppert C; Günther A; Shi W; Baumgart-Vogt E
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):E2048-57. PubMed ID: 25848047
[TBL] [Abstract][Full Text] [Related]
11. DOCK2 contributes to pulmonary fibrosis by promoting lung fibroblast to myofibroblast transition.
Guo X; Adeyanju O; Sunil C; Mandlem V; Olajuyin A; Huang S; Chen SY; Idell S; Tucker TA; Qian G
Am J Physiol Cell Physiol; 2022 Jul; 323(1):C133-C144. PubMed ID: 35584329
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of α
Decaris ML; Schaub JR; Chen C; Cha J; Lee GG; Rexhepaj M; Ho SS; Rao V; Marlow MM; Kotak P; Budi EH; Hooi L; Wu J; Fridlib M; Martin SP; Huang S; Chen M; Muñoz M; Hom TF; Wolters PJ; Desai TJ; Rock F; Leftheris K; Morgans DJ; Lepist EI; Andre P; Lefebvre EA; Turner SM
Respir Res; 2021 Oct; 22(1):265. PubMed ID: 34666752
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of microRNA-9 reduces inflammatory response and fibroblast proliferation in mice with idiopathic pulmonary fibrosis through the ANO1-mediated TGF-β-Smad3 pathway.
Dai WJ; Qiu J; Sun J; Ma CL; Huang N; Jiang Y; Zeng J; Ren BC; Li WC; Li YH
J Cell Physiol; 2019 Mar; 234(3):2552-2565. PubMed ID: 30144053
[TBL] [Abstract][Full Text] [Related]
14. Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury.
Kass DJ; Yu G; Loh KS; Savir A; Borczuk A; Kahloon R; Juan-Guardela B; Deiuliis G; Tedrow J; Choi J; Richards T; Kaminski N; Greenberg SM
Am J Pathol; 2012 May; 180(5):1963-78. PubMed ID: 22429962
[TBL] [Abstract][Full Text] [Related]
15. PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state.
Caporarello N; Meridew JA; Jones DL; Tan Q; Haak AJ; Choi KM; Manlove LJ; Prakash YS; Tschumperlin DJ; Ligresti G
Thorax; 2019 Aug; 74(8):749-760. PubMed ID: 31182654
[TBL] [Abstract][Full Text] [Related]
16. The hedgehog system machinery controls transforming growth factor-β-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis.
Cigna N; Farrokhi Moshai E; Brayer S; Marchal-Somme J; Wémeau-Stervinou L; Fabre A; Mal H; Lesèche G; Dehoux M; Soler P; Crestani B; Mailleux AA
Am J Pathol; 2012 Dec; 181(6):2126-37. PubMed ID: 23031257
[TBL] [Abstract][Full Text] [Related]
17. P311 Promotes Lung Fibrosis via Stimulation of Transforming Growth Factor-β1, -β2, and -β3 Translation.
Duan FF; Barron G; Meliton A; Mutlu GM; Dulin NO; Schuger L
Am J Respir Cell Mol Biol; 2019 Feb; 60(2):221-231. PubMed ID: 30230348
[TBL] [Abstract][Full Text] [Related]
18. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease.
Peng R; Sridhar S; Tyagi G; Phillips JE; Garrido R; Harris P; Burns L; Renteria L; Woods J; Chen L; Allard J; Ravindran P; Bitter H; Liang Z; Hogaboam CM; Kitson C; Budd DC; Fine JS; Bauer CM; Stevenson CS
PLoS One; 2013; 8(4):e59348. PubMed ID: 23565148
[TBL] [Abstract][Full Text] [Related]
19. Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected].
Krempaska K; Barnowski S; Gavini J; Hobi N; Ebener S; Simillion C; Stokes A; Schliep R; Knudsen L; Geiser TK; Funke-Chambour M
Respir Res; 2020 Jan; 21(1):25. PubMed ID: 31941499
[TBL] [Abstract][Full Text] [Related]
20. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis.
Liu G; Friggeri A; Yang Y; Milosevic J; Ding Q; Thannickal VJ; Kaminski N; Abraham E
J Exp Med; 2010 Aug; 207(8):1589-97. PubMed ID: 20643828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
